NCT05852223
Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT05852223 |
| Title | Pembrolizumab in High-risk Thyroid Cancer (NePenThe) |
| Acronym | NePenThe |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | Yes |
| Sponsors | Istituti Clinici Scientifici Maugeri SpA |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | ITA |
CKB BOOST